Unity Biotechnology (FRA:9U90) Total Liabilities : €28.26 Mil (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Unity Biotechnology Total Liabilities?

Unity Biotechnology's Total Liabilities for the quarter that ended in Mar. 2025 was €28.26 Mil.

Unity Biotechnology's quarterly Total Liabilities increased from Sep. 2024 (€29.72 Mil) to Dec. 2024 (€29.77 Mil) but then declined from Dec. 2024 (€29.77 Mil) to Mar. 2025 (€28.26 Mil).

Unity Biotechnology's annual Total Liabilities declined from Dec. 2022 (€64.44 Mil) to Dec. 2023 (€34.20 Mil) and declined from Dec. 2023 (€34.20 Mil) to Dec. 2024 (€29.77 Mil).

Unity Biotechnology Total Liabilities Historical Data

The historical data trend for Unity Biotechnology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unity Biotechnology Total Liabilities Chart

Unity Biotechnology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

60.37

57.65

64.44

34.20

29.77

Unity Biotechnology Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Liabilities	Get a 7-Day Free Trial															32.09	31.37	29.72	29.77	28.26

Unity Biotechnology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Unity Biotechnology's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	8.843	+	(18.822	+	2.1
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	29.77

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	35.967	-	6.202
	=	29.77

Unity Biotechnology's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	8.386	+	(17.276	+	2.599
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	28.26

Total Liabilities	=	Total Assets (Q: Mar. 2025 )	-	Total Equity (Q: Mar. 2025 )
	=	28.071	-	-0.19
	=	28.26

Unity Biotechnology Total Liabilities Related Terms

Thank you for viewing the detailed overview of Unity Biotechnology's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Unity Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unity Biotechnology Inc (FRA:9U90) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

UBX:USA 0YC0:UK

Address

285 East Grand Avenue, South San Francisco, CA, USA, 94080

Website

https://www.unitybiotechnology.com

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.

Unity Biotechnology Headlines

No Headlines